AZTherapies’ lead program is focused on blocking amyloid-beta aggregation, through our ALZT-OP pipeline of proprietary drugs. ALZT-OP drug candidates have a specific, large interface for binding to amyloid-beta peptides to prevent their polymerization, to interfere with amyloid plaque formation and to prevent the neurotoxic cascade and neuronal death. Able to cross the blood-brain barrier with practical efficacy, these proprietary small molecule drugs are relatively straightforward to manufacture. Patients with early cognitive impairment due to Alzheimer’s disease stand to benefit from preventing the ongoing triggers of memory loss and diminished function in Alzheimer’s disease.
AZTherapies’ lead program is focused on commercializing ALZT-OP1 via our initiated Phase III SPA trial according to the following timeline: